| Drug General Information |
| Drug ID |
D0E3HY
|
| Drug Name |
IP10 C8
|
| Synonyms |
IP10C8
|
| Indication |
Psoriasis [ICD9: 696; ICD10:L40]
|
Phase 2 |
[1]
|
|---|
| Target and Pathway |
| Target(s) |
Dipeptidyl peptidase IV |
Target Info |
Modulator |
[1]
|
|---|
| Aminopeptidase N |
Target Info |
Modulator |
[1]
|
|
BioCyc Pathway
|
Glutathione-mediated detoxification
|
|
KEGG Pathway
|
Protein digestion and absorptionhsa00480:Glutathione metabolism
|
|
Metabolic pathways
|
|
Renin-angiotensin system
|
|
Hematopoietic cell lineage
|
|
NetPath Pathway
|
IL2 Signaling Pathway
|
|
TGF_beta_Receptor Signaling Pathway
|
|
Pathway Interaction Database
|
C-MYB transcription factor network
|
|
PathWhiz Pathway
|
Glutathione Metabolism
|
|
Reactome
|
Metabolism of Angiotensinogen to Angiotensins
|
|
WikiPathways
|
Metabolism of Angiotensinogen to Angiotensins
|
|
Cardiac Progenitor Differentiation
|
|
miR-targeted genes in squamous cell - TarBase
|
|
miR-targeted genes in muscle cell - TarBase
|
|
miR-targeted genes in lymphocytes - TarBase
|
|
miR-targeted genes in leukocytes - TarBase
|
|
Glutathione metabolism
|
| References |
| REF 1 | Recent insights into the role of dipeptidyl aminopeptidase IV (DPIV) and aminopeptidase N (APN) families in immune functions. Clin Chem Lab Med. 2009;47(3):253-61. |
|---|
